EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor Necrosis Factor‐Alpha Inhibits the Replication of Patient‐Derived Archetype BK Polyomavirus While Activating Rearranged Strains

Lise Lauterbach-Rivière iD, Lucia Thuringer, Pascal Feld, Lina Kathrin Toews, Jessica Schüssler, Jonas Klinz, Lars Gläser, Stefan Lohse, Anna Sternjakob, Gilles Gasparoni, Kathrin Kattler-Lackes, Jörn Walter und 9 weitere

Journal of Medical Virology · 2025-02 · 97 (2)

DOI: 10.1002/jmv.70210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 14.02.2025. Verfasst von Lise Lauterbach-Rivière und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, Saarland University Medical Center, Homburg, Germany. Hauptthemen laut MEDLINE: BK Virus, Tumor Necrosis Factor-alpha, Virus Replication, Polyomavirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the VolkswagenStiftung, grant 9B789, the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)/Helmholtz Centre for Infect….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To date, no drugs are approved for BK polyomavirus (BKPyV) reactivation, a major cause of nephropathy after kidney transplantation. Recently, tumor necrosis factor‐α (TNF‐α) blockade has been proposed as a promising therapy, however, the effect of TNF‐α on the clinically most common archetype (ww) BKPyV remained unclear. Assays in primary renal proximal tubule epithelial cells (RPTEC) allowed efficient replication only of BKPyV strains with rearranged (rr) non‐coding control regions (NCCR), which may develop at later disease stages, but not of ww‐BKPyV. Here, we optimized culture conditions allowing robust replication of patient‐derived ww‐BKPyV, while efficiently preserving their ww‐NCCR. TNF‐α promoted rr‐BKPyV replication, while the T H 1 cytokine IFN‐γ suppressed it, also in the presence of TNF‐α. Surprisingly, TNF‐α alone was sufficient to suppress all ww‐BKPyV strains tested. Comprehensive analysis using siRNAs, and chimeric or mutated BKPyV‐strains revealed that the response to TNF‐α depends on the NCCR type, and that the NF‐κB p65 pathway but not the conserved NF‐κB binding site is essential for the TNF‐α‐induced enhancement of rr‐BKPyV replication. Our data suggest that in immunosuppressed patients with archetype‐dominated infections, TNF‐α blockade could interfere with natural TNF‐α‐mediated anti‐BKPyviral control, and this could be detrimental when IFN‐γ‐driven T H 1 responses are impaired. Ongoing inflammation, however, could lead to the selection of rearrangements responding to NCCR‐activating pathways downstream of NF‐κB p65 signaling, that may overcome the initial TNF‐α‐mediated suppression. Our findings also highlight the importance of using clinically relevant BKPyV isolates for drug testing and discovery, for which this new assay paves the way.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BK VirusTumor Necrosis Factor-alphaVirus ReplicationPolyomavirus InfectionsHumansEpithelial CellsCells, CulturedVirus ActivationInterferon-gamma

Stichwörter der Autor:innen

BK polyomavirus (BKPyV)IFN‐γTNF‐αantiviral therapyarchetypedrug discoverynon‐coding control region (NCCR)

Substanzen

Tumor Necrosis Factor-alphaInterferon-gamma

Autor:innen und Institutionen

  • Institute of Virology, Saarland University Medical Center, Homburg, Germany.
  • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University Campus, Saarbrücken, Germany.
  • Department of Genetics, Saarland University, Saarbrücken, Germany.
  • Molecular Imaging, Center for Integrative Physiology and Molecular Medicine, Saarland University, Homburg, Germany.
  • Algorithmic Bioinformatics, Center for Bioinformatics Saar, Saarland Informatics Campus, Saarland University, Saarbrücken, Germany.
  • Advanced Light and Electron Microscopy, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.

ORCID-Profile: Lise Lauterbach-Rivière

Förderung

  • This work was supported by the VolkswagenStiftung, grant 9B789, the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)/Helmholtz Centre for Infect…

Zitieren

APA

Lauterbach-Rivière, L., Thuringer, L., Feld, P., Toews, L. K., Schüssler, J., Klinz, J., Gläser, L., Lohse, S., Sternjakob, A., Gasparoni, G., Kattler-Lackes, K., Walter, J., Lauterbach, M. A., Rahmann, S., Möller, L., Laue, M., Janssen, M., Stöckle, M., Schmit, D., …, & Smola, S. (2025). Tumor Necrosis Factor‐Alpha Inhibits the Replication of Patient‐Derived Archetype BK Polyomavirus While Activating Rearranged Strains. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70210

Vancouver

Lauterbach-Rivière L, Thuringer L, Feld P, Toews LK, Schüssler J, Klinz J, et al. Tumor Necrosis Factor‐Alpha Inhibits the Replication of Patient‐Derived Archetype BK Polyomavirus While Activating Rearranged Strains. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70210

BibTeX
@article{LauterbachRivire2025,
  author = {Lauterbach-Rivière, Lise and Thuringer, Lucia and Feld, Pascal and Toews, Lina Kathrin and Schüssler, Jessica and Klinz, Jonas and Gläser, Lars and Lohse, Stefan and Sternjakob, Anna and Gasparoni, Gilles and Kattler-Lackes, Kathrin and Walter, Jörn and Lauterbach, Marcel A and Rahmann, Sven and Möller, Lars and Laue, Michael and Janssen, Martin and Stöckle, Michael and Schmit, David and Fliser, Danilo and Smola, Sigrun},
  title = {Tumor Necrosis Factor‐Alpha Inhibits the Replication of Patient‐Derived Archetype BK Polyomavirus While Activating Rearranged Strains},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {2},
  doi = {10.1002/jmv.70210}
}
Kostenlos starten →